Brief: Alteogen says its Drug Tergase Shows Excellent Immunogenicity Profile

Alteogen

05/09/2023 13:31

Sept 5 (Reuters) - Alteogen Inc  196170.KQ :
    * ALTEOGEN INC - CO'S TERGASE (NOVEL RECOMBINANT HUMAN
HYALURONIDASE INJECTION) SHOWS EXCELLENT IMMUNOGENICITY PROFILE
    * ALTEOGEN INC - EXPECTS TERGASE WILL REPLACE COMMERCIALLY
AVAILABLE ANIMAL-DERIVED HYALURONIDASE PRODUCTS AND THEIR
SIGNIFICANT DISADVANTAGES
    * ALTEOGEN INC - COMPARED WITH OTHER COMMERCIALLY AVAILABLE
HYALURONIDASE PRODUCTS, TERGASE SHOWED NO INCIDENCE OF ANTI-DRUG
ANTIBODIES
    * ALTEOGEN INC - CURRENTLY, TERGASE IS UNDERGOING
PHARMACEUTICAL
APPROVAL PROCESS BY MINISTRY OF FOOD AND DRUG SAFETY
    * ALTEOGEN INC - EXPECTED TO OBTAIN PRODUCT APPROVAL BETWEEN
END
OF 2023 AND BEGINNING OF 2024 AT LATEST

Source text for Eikon:  ID:nPn9yz6Xga 
Further company coverage:  196170.KQ 

 ((Reuters.Briefs@thomsonreuters.com;))